| Item type: | Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journal or Publication Title: | Oncology | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | KARGER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Place of Publication: | BASEL | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 73 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of Issue or Book Chapter: | 1-2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | pp. 21-25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: | 2007 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Institutions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Neurologie | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Identification Number: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Classification: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Keywords: | ACTIVATED-RECEPTOR-GAMMA; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; MALIGNANT GLIOMA; CLINICAL-TRIALS; CYCLOOXYGENASE-2; EXPRESSION; APOPTOSIS; CANCER; GROWTH; glioblastoma; anaplastic glioma; low-dose chemotherapy; drug resistance; capecitabine; temozolomide; pioglitazone; rofecoxib | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Published | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Created at the University of Regensburg: | Unknown | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Item ID: | 29320 |
Web of ScienceAbstract
Objectives: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. Methods: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy ( capecitabine or temozolomide) in patients with high-grade gliomas ( glioblastoma or ...
Abstract
Objectives: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. Methods: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy ( capecitabine or temozolomide) in patients with high-grade gliomas ( glioblastoma or anaplastic glioma). Results: Fourteen patients were evaluable for response and toxicity. Major side effects were palmoplantar erythema, edema and motor neuropathy grade 3. Disease stabilizations lasting longer than 3 months were noted in 4 of 14 patients ( 29%). Clinical responses did not correspond to immunohistochemical staining for cyclooxygenase 2, peroxisome proliferator-activated receptor- gamma and CD31. Discussion: The study demonstrates that this novel regimen is moderately active and well tolerated in patients with high-grade gliomas. As a comparably small proportion of patients responded, the regimen might only be suitable for a subset of highly selected patients. Copyright (c) 2008 S. Karger AG, Basel.
Metadata last modified: 29 Sep 2021 07:39
Altmetric